
It balances identified risks with clinical benefit using compounds identified at known levels and other relevant biological tests. It is written in accordance with ISO 10993-17 and is typically used in conjunction with chemical characterization testing according to ISO 10993-18.

It includes:
It balances the detected risks with clinical benefit to the patient. (This looks at the process versus biological and chemical testing to address the overall risk compared to a device's material and patient benefit.)
Available for address:
Biological Evaluation Plan (BEP), EUROLAB It is an initial risk assessment provided by and aims to meet the objectives of ISO 10993-1, clause 4 “General principles applied to the biological evaluation of medical devices”. The first part of this article specifically states that “Biological evaluation should be planned, implemented and documented by knowledgeable and experienced professionals.” The BEP takes into account the materials, processing, and historical use of the device. The output is a signed biological assessment plan that recommends the testing and information needed to demonstrate device safety.
Biological Assessment Report (BER), ISO 10993-1: 2018, clause 7: “Expert surveyors with the necessary knowledge and experience:
Opinion is given about a specific device state. This is most appropriate when the interview does not have to be complex or broadly implemented. Usually this is a 1-2 page document signed by a consultant. This is a high level review of what is done following the recommendations on next steps (tests and / or further risk assessment).
Evaluating changes in regulatory standards for which previous tests were carried out against the most recent regulatory standards.
This usually includes:
EUROLAB, with its highly expert team and internationally accredited laboratories, Toxicological Risk Analysis It performs all test, analysis, measurement, evaluation and report generation services completely and reliably.
